BRAF and neoplasm: Another common mutation that can be targeted therapeutically is the V600E mutation in the v-RAF murine sarcoma viral oncogene homolog B1 (BRAF), which constitutively activates the BRAF kinase, resulting in sustained extracellular signal-related kinase (ERK) signaling and increased tumor growth66.